Lonza Capsugel in the news

Lonza Capsugel advances supplement delivery with innovative capsule technologies like capsule-in-capsule and scented coatings, enhancing bioavailability and consumer appeal for challenging ingredients.

A study confirmed Capsugel® Enprotect® capsules maintain robust gastric integrity and targeted release in various digestive conditions, including challenging high-fat meals.

A new study confirms Lonza Capsugel's Enprotect capsules maintain gastric integrity in various physiological states, protecting sensitive compounds until intestinal release.

Capsugel® Enprotect® capsules maintain their integrity in the stomach across different meal conditions, ensuring targeted release in the intestine, as confirmed by a new study using a dynamic gastrointestinal model.

Lonza Capsugel's Licaps® DUOCAP® capsule-in-capsule technology improves the targeted delivery and protection of acid-sensitive enzymes in the GI tract, as demonstrated by new peer-reviewed research.

Lonza Capsugel's Licaps DUOCAP capsule-in-capsule technology significantly improves the delivery and protection of acid-sensitive digestive enzymes in the gastrointestinal tract, as validated by new peer-reviewed research.

Lonza Capsugel's new research confirms its Licaps® DUOCAP® technology enhances the protection and targeted delivery of acid-sensitive enzymes, significantly improving their effectiveness in the GI tract.

The menopause and women's health ingredients market is forecast to grow significantly, driven by specialized formulations addressing distinct health outcomes and utilizing key ingredients like collagen.

Lonza Group's stock is trading steadily as investors evaluate its latest earnings, significant growth investments in biologics manufacturing, and strategic positioning as a leading contract development and manufacturing organization.

Lonza reported strong Q1 results with increased sales and improved EBITDA margin, raised full-year guidance, and announced the sale of its Capsules & Health Ingredients division along with a CHF 500 million share buyback.

Lonza Capsugel celebrates 25 years of its UC-II collagen, a highly researched ingredient supporting joint health in humans and expanding into pet nutrition.

Lonza has restated its 2025 financial results to reflect the sale of its Capsules & Health Ingredients division to Lone Star Funds.

Lonza Group AG shares dropped following a reduction in medium-term profitability targets and the announcement of a CEO transition.

Lonza has agreed to sell its Capsules & Health Ingredients business unit to Lone Star Funds with global legal support from Linklaters and TT&A.

Lonza is divesting its capsule and health ingredients division to Lone Star for $3bn to focus on its core CDMO operations.

Lonza is divesting its Capsules & Health Ingredients business to Lone Star Funds for CHF 2.3 billion, retaining a 40% stake, to become a pure-play CDMO.

Banks are pre-marketing debt for the carve-out of Lonza's capsules business.

Lonza Capsugel discusses opportunities in plant-based and organic dietary supplements, highlighting their Organicaps and the technical and market advantages of various vegan capsule polymers.

Lonza Capsugel will showcase innovative capsule technologies, sustainable manufacturing, and ingredient solutions at Vitafoods Europe 2026.

Lone Star Funds is acquiring Lonza Group AG's Capsules & Health Ingredients division, with Lonza retaining a 40% stake.